Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.

AIDS (London, England) - 23 Apr 2007

Napravnik Sonia, Keys Jessica R, Quinlivan E Byrd, Wohl David A, Mikeal Oksana V, Eron Joseph J

Abstract excerpt

BACKGROUND: HIV-1 triple-class antiretroviral drug resistance (TC-DR) may substantially limit therapeutic options and compromise clinical outcomes. OBJECTIVE: To estimate TC-DR prevalence and incidence, and identify risk factors for TC-DR acquisition. METHODS: We identified patients in the University of North Carolina HIV Cohort Study with TC-DR HIV-1 variants. Nucleos(t)ide reverse transcriptase inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4 Lymphocyte Count

Share to Drug Administration Schedule

Share to Drug Resistance, Multiple, Viral

Share to HIV Infections

Share to Viral Load

Source

Identifiers

PMID: 17415037
DOI: 10.1097/QAD.0b013e32805e8764

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.PMID 17415037Read ↗

Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.Semantic proximity Read ↗

Transmitted Drug Resistance Among Human Immunodeficiency Virus (HIV)-1 Diagnoses in the United States, 2014-2018.Semantic proximity Read ↗

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.Semantic proximity Read ↗

A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse transcriptase and co-receptor tropism database from 2003 to 2012.Semantic proximity Read ↗

Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007.Semantic proximity Read ↗

Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.Semantic proximity Read ↗

Transmitted Antiretroviral Drug Resistance in Individuals with Newly Diagnosed HIV Infection: South Carolina 2005–2009Semantic proximity Read ↗

New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations.Semantic proximity Read ↗

High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda.Semantic proximity Read ↗

Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy.Semantic proximity Read ↗

Drug Resistance in HIV Following First-line ART Failure: Insights from a Cross-sectional Study in India.Semantic proximity Read ↗

Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.